Trial Profile
A Phase III Study Comparing Single-Agent Olaparib or the Combination of Cediranib and Olaparib to Standard Platinum-Based Chemotherapy in Women With Recurrent Platinum-Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 08 Apr 2024
Price :
$35
*
At a glance
- Drugs Cediranib (Primary) ; Olaparib (Primary) ; Carboplatin; Doxorubicin liposomal; Gemcitabine; Paclitaxel
- Indications Carcinoma; Endometrial cancer; Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Registrational; Therapeutic Use
- 24 Oct 2023 Results assessing pre-specified overall survival analysis, presented at the 48th European Society for Medical Oncology Congress.
- 12 Sep 2023 Planned End Date changed from 30 Dec 2023 to 9 Aug 2024.
- 22 Oct 2022 Planned End Date changed from 29 Sep 2022 to 30 Dec 2023.